116 related articles for article (PubMed ID: 3079324)
21. [Phase I study of human lymphoblastoid alpha-interferon on malignant tumor].
Furue H
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):977-83. PubMed ID: 3963861
[TBL] [Abstract][Full Text] [Related]
22. The new alpha interferons.
Balmer CM
Drug Intell Clin Pharm; 1985 Dec; 19(12):887-93. PubMed ID: 3910384
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behçet disease].
Stadler R; Bratzke B; Orfanos CE
Hautarzt; 1987 Aug; 38(8):453-60. PubMed ID: 3654216
[TBL] [Abstract][Full Text] [Related]
24. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
25. Treatment of neuroendocrine gut and pancreatic tumors with interferons.
Oberg K
Acta Chir Scand Suppl; 1989; 549():56-62. PubMed ID: 2538982
[No Abstract] [Full Text] [Related]
26. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of leukemias and lymphomas by interferons: II. Phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha+].
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Schwarzenberg L; Machover D; Ribaud P; de Vassal F
Biomed Pharmacother; 1982 Mar; 36(2):112-6. PubMed ID: 7126777
[TBL] [Abstract][Full Text] [Related]
28. [Clinical trial of human lymphoblastoid interferon on advanced malignancy].
Usui N; Ogawa M; Inagaki J; Horikoshi N; Inoue K; Miyamoto H; Ikeda K; Nakada H; Adachi K; Okada Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2324-9. PubMed ID: 6357102
[TBL] [Abstract][Full Text] [Related]
29. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
31. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
32. The alpha interferons: clinical overview.
Spiegel RJ
Semin Oncol; 1987 Jun; 14(2 Suppl 2):1-12. PubMed ID: 3296210
[TBL] [Abstract][Full Text] [Related]
33. Intron A (interferon alfa-2b): clinical overview and future directions.
Spiegel RJ
Semin Oncol; 1986 Sep; 13(3 Suppl 2):89-101. PubMed ID: 3532338
[TBL] [Abstract][Full Text] [Related]
34. Increasing effectiveness of interferon-alpha for malignancies.
Lindner DJ; Kalvakolanu DV; Borden EC
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-99-S9-104. PubMed ID: 9208879
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Taylor W; Laszlo J
Cancer Treat Rep; 1985; 69(7-8):817-20. PubMed ID: 4016792
[TBL] [Abstract][Full Text] [Related]
36. Importance of treatment regimen of interferon as an antitumor agent.
Lee SH; Chiu H; Rinderknecht E; Sabo W; Stebbing N
Cancer Res; 1983 Sep; 43(9):4172-5. PubMed ID: 6347366
[TBL] [Abstract][Full Text] [Related]
37. [Effect of interferon-alpha 2 (E. coli) in hairy cell leukemia].
Hofmann V; Scheel A; Schwarzmeier J; Talstad I; Varini M; Kaplan S; Sauter C; Fehr J
Schweiz Med Wochenschr; 1985 Feb; 115(7):235-8. PubMed ID: 3872477
[TBL] [Abstract][Full Text] [Related]
38. Circadian variations in myelosuppressive activity of interferon-alpha in mice: identification of an optimal treatment time associated with reduced myelosuppressive activity.
Koren S; Fleischmann WR
Exp Hematol; 1993 Apr; 21(4):552-9. PubMed ID: 8462664
[TBL] [Abstract][Full Text] [Related]
39. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
[TBL] [Abstract][Full Text] [Related]
40. Interferon-alpha therapy of renal cancer.
Neidhart JA; Gagen MM; Young D; Tuttle R; Melink TJ; Ziccarrelli A; Kisner D
Cancer Res; 1984 Sep; 44(9):4140-3. PubMed ID: 6378379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
